



1751 BOX/504

**BEST AVAILABLE COPY**

Attorney Docket No.: 4318.224-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bisgaard-Frantzen et al. Confirmation No: 7527

Serial No.: 09/902,188 Group Art Unit: 1751

Filed: July 10, 2001 Examiner: To be assigned

For: Amylase Variants

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

**RECEIVED**  
OCT 03 2001  
**TC 1700**

Box Sequence  
Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Response to Notice to Comply with Sequence Rules
- 2. Sequence Listing
- 3. Copy of Notice to Comply with Sequence Rules
- 5. Disk Containing Sequence Listing


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence  
Commissioner for Patents  
Washington, DC 20231

on September 26, 2001.

Kelley O'Patry  
(name of person mailing paper)

  
(signature of person mailing paper)



**BEST AVAILABLE COPY**  
 UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/902,188	07/10/2001	Henrik Bisgard-Frantzen	4318.224-US

**CONFIRMATION NO. 7527**

25908  
 NOVOZYMES NORTH AMERICA, INC.  
 C/O NOVO NORDISK OF NORTH AMERICA, INC.  
 405 LEXINGTON AVENUE, SUITE 6400  
 NEW YORK, NY 10174

**FORMALITIES LETTER**



\*OC00000006360134\*

Date Mailed: 07/30/2001

**RECEIVED**

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

OCT 3 2001  
**TC 1700**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

*148*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

**BEST AVAILABLE COPY**  
PART 2 - COPY TO BE RETURNED WITH RESPONSE